Sugi Predict

Sugi Predict / Compounds / SCHEMBL4448319

SCHEMBL4448319

SCHEMBL4448319

C[C@H](N)c1ccc(C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 1/20 0.57
▸ TSHR P16473 2/20 0.55
▸ TP53 P04637 1/20 0.55
▸ ROCK2 O75116 2/20 0.50
▸ ROCK1 Q13464 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ ADRB2 P07550 1/20 0.48
▸ SRD5A2 P31213 2/20 0.48
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA3 P07451 1/20 0.46
▸ TYR P14679 1/20 0.46
▸ DRD1 P21728 1/20 0.46
▸ CA4 P22748 1/20 0.46
▸ CA6 P23280 1/20 0.46
▸ CA5A P35218 1/20 0.46
▸ CA7 P43166 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129856 1.00 ANPEP (0.57) ANPEPTSHRTP53ROCK2ROCK1
Terephthalic Acid SCHEMBL8743590 1.00 ANPEP (0.57) ANPEPTSHRTP53ROCK2ROCK1
SCHEMBL4878931 1.00 ANPEP (0.57) ANPEPTSHRTP53ROCK2ROCK1
Hydrochloric Acid SCHEMBL2406930 0.98 ANPEP (0.55) ANPEPTSHRTP53ROCK2ROCK1
Hydrochloric Acid SCHEMBL872072 0.98 ANPEP (0.55) ANPEPTSHRTP53ROCK2ROCK1
Hydrochloric Acid SCHEMBL4532593 0.98 ANPEP (0.55) ANPEPTSHRTP53ROCK2ROCK1
Sulfuric Acid SCHEMBL2295357 0.92 ANPEP (0.50) ANPEPTSHRTP53ROCK2ROCK1
Sulfuric Acid SCHEMBL3917965 0.92 ANPEP (0.50) ANPEPTSHRTP53ROCK2ROCK1
Sulfuric Acid SCHEMBL3913765 0.92 ANPEP (0.50) ANPEPTSHRTP53ROCK2ROCK1
Benzoic Acid SCHEMBL28384787 0.87 DAO (0.58) ANPEPTSHRALDH1A1SMN1; SMN2SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492174-B2 Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases NXERA PHARMA UK LIMITED (GB) 2025-12-09 — — US disclosed
US-20250179036-A1 MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES NXERA PHARMA UK LIMITED (GB) 2025-06-05 — — US disclosed
EP-4397654-A1 EP4 ANTAGONIST COMPOUND AS WELL AS SALT, POLYMORPH, AND USE THEREOF Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2024-07-10 — — EP disclosed
EP-4286371-A1 PYRAZOLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shenzhen Zhongge Biological Technology Co., Ltd. (CN) 2023-12-06 — — EP disclosed
EP-3736276-B1 THIENOCYCLIC COMPOUND AND SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI YUYAO BIOTECH LTD (CN) 2023-03-01 — — EP disclosed
US-20220411364-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LIMITED (GB) 2022-12-29 — — US disclosed
US-20210403460-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF ISOCURE BIOSCIENCES INC (US) 2021-12-30 — — US disclosed
US-11149032-B2 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof ISOCURE BIOSCIENCES INC. (US) 2021-10-19 — — US disclosed
US-20210139497-A1 THIENOCYCLIC COMPOUND AND SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF Shanghai Yuyao Biotech Ltd. (CN) 2021-05-13 — — US disclosed
WO-2021069927-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-15 — — WO disclosed
WO-2006116157-A2 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2006-11-02 — — WO disclosed
US-20060167014-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2006-07-27 — — US disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 — — WO disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 — — WO disclosed
EP-1029851-B1 PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2005-04-20 — — EP disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 — — US disclosed
US-20030055064-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2003-03-20 — — US disclosed
US-20030018034-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2003-01-23 — — US disclosed
US-6455528-B1 TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 — — US disclosed
EP-1029851-A1 PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-08-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403460-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF IDH1, IDH2, IDH3A ANPEP 2236/4885TSHR 4834/4885TP53 23/4885
US-20030055064-A1 Piperazine compounds and medicinal use thereof TNF, IL5, CCR10 ANPEP 1164/4885TSHR 1550/4885TP53 3861/4885
US-12492174-B2 Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases PTGER4, PTGER1, PTGER2 ANPEP 3747/4885TSHR 480/4885TP53 4357/4885
US-20030018034-A1 Piperazine compounds and medicinal use thereof TNF, IL5, CCR10 ANPEP 1132/4885TSHR 1532/4885TP53 3853/4885
US-20060167014-A1 Piperazine compounds and medicinal use thereof TNF, CCR10, RELA ANPEP 1421/4885TSHR 630/4885TP53 3535/4885
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 ANPEP 3213/4885TSHR 894/4885TP53 4625/4885
US-11149032-B2 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof IDH1, IDH2, IDH3A ANPEP 2236/4885TSHR 4834/4885TP53 23/4885
US-20220411364-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS PTGER1, PTGER4, PTGER2 ANPEP 4003/4885TSHR 362/4885TP53 4230/4885
US-20210139497-A1 THIENOCYCLIC COMPOUND AND SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF PTGER4, PTGER1, PTGES ANPEP 3995/4885TSHR 558/4885TP53 1685/4885
US-20250179036-A1 MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES PTGER4, PTGER1, PTGER2 ANPEP 3747/4885TSHR 480/4885TP53 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.